Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Alumis Inc. Common StockNASDAQ: ALMS
Other Current Assets · Q2 FY2026 · quarter ended Jun 2026
Other current assets falls 66.1% from a year ago
Other current assets stood at $7.93M at the end of Q2 FY2026, down 66.1% from a year earlier and up 17.8% from the prior quarter. Over 3 fiscal years it compounded at +233.6% a year.
Context
- Other current assets amounted to 1.4% of total assets at the end of Q2 FY2026, down 2.4 pp from a year earlier.
- Other current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps falling in the next quarterly balance sheet after a -66.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 7.65M USD
- Year-over-year change
- +903.7%
- 3-year CAGR
- +233.6%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.65M | +903.7% |
| FY2024 | 2024-12-31 | 762K | +266.3% |
| FY2023 | 2023-12-31 | 208K | +1.0% |
| FY2022 | 2022-12-31 | 206K | — |
Other Current Assets vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -66.1% is the 7th highest of 8, against a peer median of -34.3%.
- Other current assets amounts to 1.4% of total assets for ALMS, versus a peer median of 1.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $25.75M USD | +303.8% | +38.5% | 5.1% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $7.93M USD | -66.1% | +233.6% | 1.4% |
| Mar 2026 | $6.83M USD | +10919.4% | +74.6% | 6.8% | |
| Mar 2026 | $3.91M USD | -26.2% | +1.6% | 1.2% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €3.43M EUR | — | — | 2.1% |
| Mar 2026 | €2.91M EUR | -49.1% | +31.1% | 5.9% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $1.36M USD | -54.8% | +33.9% | 1.3% |
| Mar 2026 | $1.17M USD | -34.3% | -24.1% | 1.8% | |
| Mar 2026 | $0 USD | -100.0% | +59.8% | 0.0% | |
| Dec 2025 | $0 USD | — | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | -34.3% | +33.9% | 1.8% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.